Predictive oncology announces planned european launch of its chemofx® treatment selection marker and tumor profiling assay

Initial plans target european clinical trials while providing standard testing to clinicians for individual patients there are an estimated 250,000 gynecologic cancers diagnosed annually across europe pittsburgh, jan. 16, 2025 (globe newswire) -- predictive oncology inc. (nasdaq: poai), a leader in ai-driven drug discovery, today announced plans to launch its validated flagship live cell chemofx® drug response assay in europe and expanded availability in the united states. the chemofx® treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time.
POAI Ratings Summary
POAI Quant Ranking